Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2019--
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that it will report financial results for the
fourth quarter and year ending December 31, 2018 on Thursday, February
7, 2019, after the U.S. financial markets close.
Management will provide an update on the Company and discuss fourth
quarter and year-end 2018 results as well as expectations for the future
via conference call on Thursday, February 7, 2019 at 4:30 pm ET. To
access the call, please dial 800-667-5617 (domestic) or 334-323-0509
(international) five minutes prior to the start time and refer to
conference ID 4263166. A replay of the call will be available beginning
at 7:30 pm ET on the day of the call. To access the replay, please dial
888-203-1112 (domestic) or 719-457-0820 (international) and refer to
conference ID 4263166.
A live audio webcast of the call will be available on the Investors
section of the Company’s website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class of
innovative medicines with the potential to improve the lives of people
afflicted with rare genetic, cardio-metabolic, hepatic infectious, and
central nervous system (CNS)/ocular diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform. ONPATTRO® (patisiran) lipid complex
injection, available in the U.S. for the treatment of the polyneuropathy
of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is
Alnylam’s first U.S. FDA-approved RNAi therapeutic. In the EU, ONPATTRO
is approved for the treatment of hATTR amyloidosis in adults with stage
1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of
investigational medicines, including three product candidates that are
in late-stage development. Looking forward, Alnylam will continue to
execute on its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines to address the needs of patients who have
limited or inadequate treatment options. Alnylam employs over 1,000
people worldwide and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190131005646/en/
Source: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom